INmune Bio Inc. Common stock (INMB)

Price$1.26

Value ScoreD

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-35.51%

Price vs S&P 500 (4W)-11.88%

VGM Score48.35

Market Capitalization$33.50M

All Metrics

Book Value / Share (Quarterly)$0.74

P/TBV (Annual)1.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-48.68%

Cash Flow / Share (Quarterly)$-0.76

Price vs S&P 500 (YTD)-27.39%

Net Profit Margin (TTM)-19478.00%

EPS (TTM)$-1.69

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-1.69

Revenue Growth (5Y)37.97%

EPS (Annual)$-1.86

ROI (Annual)-195.26%

Net Profit Margin (5Y Avg)-87209.13%

Cash / Share (Quarterly)$0.80

ROA (Last FY)-141.98%

Revenue Growth TTM (YoY)257.14%

EBITD / Share (TTM)$-1.67

ROE (5Y Avg)-97.66%

Operating Margin (TTM)-19810.00%

Cash Flow / Share (Annual)$-0.89

P/B Ratio1.71x

P/B Ratio (Quarterly)1.53x

Net Income / Employee (Annual)$-2,187,300

EV / Revenue (TTM)242.79x

Net Interest Coverage (TTM)-52.34x

ROA (TTM)-128.78%

EPS Incl Extra (Annual)$-1.86

Current Ratio (Annual)3.55x

Quick Ratio (Quarterly)4.11x

3-Month Avg Trading Volume0.43M

52-Week Price Return-82.86%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)669.95x

Asset Turnover (Annual)0.00x

52-Week High$11.64

Operating Margin (5Y Avg)-88339.48%

EPS Excl Extra (Annual)$-1.86

Tangible BV CAGR (5Y)1.12%

26-Week Price Return-27.59%

Quick Ratio (Annual)3.48x

13-Week Price Return-0.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.24x

Enterprise Value$12.14M

Revenue / Share Growth (5Y)20.11%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-21.00%

Revenue / Employee (Annual)$2,400

Pretax Margin (Annual)-91866.00%

Cash / Share (Annual)$0.93

3-Month Return Std Dev77.51%

Net Income / Employee (TTM)$-1,981,000

ROE (Last FY)-195.26%

Net Interest Coverage (Annual)-52.22x

EPS Basic Excl Extra (Annual)$-1.86

Receivables Turnover (TTM)0.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.69

Receivables Turnover (Annual)0.05x

ROI (TTM)-170.86%

P/S Ratio (TTM)669.95x

Pretax Margin (5Y Avg)-87209.13%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.88

Price vs S&P 500 (52W)-107.22%

Year-to-Date Return-19.23%

5-Day Price Return-9.35%

EPS Normalized (Annual)$-1.86

ROA (5Y Avg)-72.94%

Net Profit Margin (Annual)-91866.00%

Month-to-Date Return-10.64%

EBITD / Share (Annual)$-1.91

Operating Margin (Annual)-94766.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.47%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.69

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)-19478.00%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)-8.65%

Beta1.05x

Revenue / Share (TTM)$0.00

ROE (TTM)-170.86%

52-Week Low$1.09

vGradeD

gGradeA

mGradeD

vgmGradeC

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.10

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
INMBINmune Bio Inc. Common stock	D	A	D	$1.26
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

INmune Bio is a clinical-stage biotechnology company developing immunotherapies designed to reprogram patients' innate immune systems to combat cancer. The company's pipeline includes multiple candidates across oncology and other therapeutic areas, positioned to address significant unmet medical needs in immuno-oncology.